SIRPA and primary cutaneous T-cell non-Hodgkin lymphoma: Because CD47 is also expressed on macrophages, linking anti-PD-1/PD-L1 therapy with anti-CD47/SIRPα as a fusion protein may be beneficial for CTCL treatment, as it has been shown to have good efficacy against melanoma in vitro, even when anti-PD-L1 monotherapy alone was insufficient [26].